FOR IMMEDIATE RELEASE December 4, 2025 HEADLINE New Phase III Data for Breezula® (Clascoterone) Shows Strong Hair-Count Gains and Robust Safety in Androgenetic Alopecia Trials SUMMARY Topical androgen receptor inhibitor Breezula® (clascoterone 5% solution) has met its co-primary endpoints in two Phase III trials, showing substantial improvements in scalp hair count over vehicle — raising hopes for a new non-systemic therapy for pattern hair loss. New York hair-loss special

FOR IMMEDIATE RELEASE December 2, 2025 Taipei, Taiwan HEADLINE New Taiwanese Mouse Study Identifies Fat-Cell Signaling Pathway That Triggers Hair Regrowth SUMMARY A newly released study from researchers at National Taiwan University (NTU) shows that topical application of specific fatty acids stimulated rapid and robust hair regrowth in hairless mice. New York dermatologist Dr. Dennis Porto notes that while the findings are compelling, translation to humans remains uncerta

FOR IMMEDIATE RELEASE HEADLINE Cemiplimab Continues to Show Strong Outcomes for Advanced Cutaneous Squamous Cell Carcinoma SUMMARY Cemiplimab, the first FDA-approved PD-1 inhibitor specifically indicated for advanced cutaneous squamous cell carcinoma (cSCC), continues to demonstrate high response rates and durable tumor control in ongoing clinical research. New York Mohs surgeon Dr. Dennis Porto highlights its importance as an option for patients with aggressive or unresectab

FOR IMMEDIATE RELEASE HEADLINE Medicus Microneedling-Based Therapy Enters Clinical Evaluation for Basal Cell Carcinoma SUMMARY A novel microneedling-based drug delivery platform is being investigated as a potential non-surgical treatment for basal cell carcinoma (BCC). New York Mohs surgeon Dr. Dennis Porto comments on the promise and limitations of this investigational approach as early trial data emerge. BACKGROUND: BASAL CELL CARCINOMA AND CURRENT TREATMENTS Basal cell car